Objective To observe the clinical effects of Jianpi Jiedu decoction combined with apatinib mesylate on advanced primary liver cancer ( PLC). Methods 60 patients with PLC were divided into three groups according to the random number table method. 20 cases in Chinese medicine group were treated by Jianpi Jiedu decoction. 20 cases in western medicine group were treated by apatinib mesylate orally. 20 cases in combined group were treated by Jianpi Jiedu decoction and apatinib mesylate. All groups were treated for 8 weeks. The decrease rate of serum alpha-fetoprotein ( AFP) and the changes of CD4＜sup＞+＜/sup＞, CD8＜sup＞+＜/sup＞and natural killer ( NK) cells in the three groups were compared. The efficacy and adverse reactions of solid tumors of the three groups were counted. Results The effective rate of AFP in the combined group was higher than that in the western medicine group ( P ＜ 0. 05). After treatment, the levels of CD4＜sup＞+＜/sup＞, CD8＜sup＞+＜/sup＞and NK in Chinese medicine group and the combined group were increased ( P＜ 0. 05), and the CD4＜sup＞+＜/sup＞, CD8＜sup＞+＜/sup＞and NK in the western medicine group were decreased ( P ＜ 0. 05). After treatment, the CD4＜sup＞+＜/sup＞, CD8＜sup＞+＜/sup＞and NK in Chinese medicine group were higher than that in the combined group ( P ＜0. 05), and the CD4＜sup＞+＜/sup＞, CD8＜sup＞+＜/sup＞and NK in combined group were higher than that in the western medicine group ( P ＜0. 05). The objective response rate of the combined group was higher than that of the Chinese medicine group and the western medicine group ( P ＜ 0. 05). The incidence of proteinuria in western medicine group was higher than that in the combined group ( P ＜ 0. 05). Conclusion Jianpi Jiedu decoction combined with apatinib mesylate is effective in the treatment of advanced PLC, which can significantly reduce AFP levels, increase CD4＜sup＞+＜/sup＞, CD8＜sup＞+＜/sup＞and NK levels, and has good safety.%目的观察健脾解毒方联合甲磺酸阿帕替尼片治疗晚期原发性肝癌 (PLC) 的临床疗效.方法将60例晚期PLC患者按随机数字表法分为3组.中药组20例予健脾解毒方口服治疗;西药组20例予甲磺酸阿帕替尼片口服治疗;联合组20例予健脾解毒方+甲磺酸阿帕替尼片口服治疗.3组均治疗8周, 比较3组治疗后血清甲胎蛋白 (AFP) 下降率、3组治疗前后CD4＜sup＞+＜/sup＞、CD8＜sup＞+＜/sup＞及自然杀伤 (NK) 细胞变化情况, 并统计3组实体瘤疗效及不良反应发生情况.结果联合组治疗后AFP有效率高于西药组 (P＜0.05).治疗后中药组、联合组CD4＜sup＞+＜/sup＞、CD8＜sup＞+＜/sup＞、NK细胞均升高 (P＜0.05), 西药组CD4＜sup＞+＜/sup＞、CD8＜sup＞+＜/sup＞、NK细胞均降低 (P＜0.05).治疗后中药组CD4＜sup＞+＜/sup＞、CD8＜sup＞+＜/sup＞、NK细胞均高于联合组 (P＜0.05), 联合组CD4＜sup＞+＜/sup＞、CD8＜sup＞+＜/sup＞、NK细胞均高于西药组 (P＜0.05).联合组客观缓解率高于中药组、西药组 (P＜0.05).西药组蛋白尿发生率高于联合组 (P＜0.05).结论健脾解毒方联合甲磺酸阿帕替尼片治疗晚期PLC疗效确切, 可明显降低患者AFP水平, 升高CD4＜sup＞+＜/sup＞、CD8＜sup＞+＜/sup＞、NK细胞水平, 安全性良好.
展开▼
